This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
For diagnosis, therapy, or imaging of certain disease, specifi c targeting is an important issue. To this end, antibodies have been widely used to target molecules of interest and made a tremendous contribution to a wide range of applications based on molecular recognition (Jayasena, 1999) . The IgG2a CD3-specifi c transplant rejection drug OKT3 (muromonab) was the fi rst FDA-approved therapeutic antibody (Hooks et al., 1991) . Subsequently, diverse therapeutic antibodies have been applied to treat diseases (Knight et al., 1993; Mazumdar and Greenwald, 2009; Pageau, 2009; Banaszynski and Kolesar, 2013) . However, many limitations have been identifi ed, including diffi culties with production, immunogenicity, expensiveness, reoptimization with each new batch, sensitivity to temperature, and irreversible denaturation. Recently, chemical antibody called aptamer has emerged as a new targeting molecule.
Aptamers consist of nucleic acids that bind to diverse targets with high affi nity and selectivity. They are screened through an in vitro process and usually have higher binding affi nity than traditional antibody. Aptamers are produced chemically, and no or little batch-to-batch variation is observed during aptamer production. Furthermore, aptamers can be easily modifi ed to chemically conjugate with other molecules. Aptamer can also undergo reversible denaturation at high temperature, making it a very versatile tool for drug loading and antidote application. Moreover, aptamers elicit little or no immunogenicity in therapeutic applications (Eyetech Study Group, 2002; Foy et al., 2007; Zhu et al., 2012a) . The fi rst aptamer-based drug called Macugen (pegaptanib) was FDA-approved in 2004 (Ruckman et al., 1998) , and many studies proceeded to test effi cacy.
Here, the up-to-date methods for SELEX processes are introduced. Moreover, diverse strategies to increase aptamer stability in biological fl uid are discussed. Also, its utility as a targeting molecule for imaging, diagnosis, therapy and targeted drug delivery are discussed.
WHAT IS AN APTAMER?
Aptamer is a single-stranded nucleic acid oligomer made of RNA or DNA which can bind to specifi c target molecule with high affi nity and selectivity. Secondary or tertiary struc-
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Biomol Ther 21(6), 423-434 (2013) tures of aptamers allow target binding and determine target specifi city and affi nity (Ellington and Szostak, 1990; Tuerk and Gold, 1990; Schneider et al., 1995; Mosing et al., 2005; Chen et al., 2009) . In the early 1990s, several research laboratories were independently experimenting with what Jack W. Szostak's group termed "in vitro selection" (Ellington and Szostak, 1990) . To describe molecular recognition properties for what were nucleic acid-based ligands, they coined the term 'aptamer' using the Latin word "aptus", meaning "fi tting" and the Greek word ''meros'', meaning "particle". But naming aptamers was not nearly as interesting as discovering that their properties compete quite well with those of antibodies. Targets of aptamer may include, but are not limited to, metal ions (Kawakami et al., 2000) , small organic compounds (Mann et al., 2005) , biological cofactors (Lauhon and Szostak, 1995; Holland et al., 2000) , metabolites (Bruno et al., 2008) , proteins (Ruckman et al., 1998; White et al., 2001; Savla et al., 2011) and whole organisms such as a virus (Tang et al., 2009) , bacteria (Hamula et al., 2011) , yeast (Kolesnikova et al., 2010) , or mammalian cell . Aptamers can be easily modifi ed by various chemical reactions to introduce functional groups and/or nucleotide extensions. Aptamers can be easily conjugated to therapeutic molecules such as drugs, drug containing carriers, toxins, or photosensitizers. Thus, aptamers are promising escort molecules for drug delivery systems.
NEW METHODS FOR IN VITRO SELECTION OF AP-TAMERS
SELEX is an in vitro selection method designed to identify aptamers that are selectively bound to target molecules with high affi nity. Substantive studies on aptamers have progressed since the in vitro selection process called SELEX was fi rst reported by Gold's and Szostak's groups (Ellington and Szostak, 1990; Tuerk and Gold, 1990) . First, the nucleic acid library, which consists of 10 14 -10 15 random oligonucleotide strands, is incubated with a target molecule. Then, the target-bound oligonucleotide strands are separated from the unbound strands. The target-bound DNA or RNA strands are eluted from the target molecule and amplifi ed via polymerase chain reaction to seed a new pool of nucleic acids. This selection process is continued for 6-15 rounds with increasingly stringent conditions, which ensure that the nucleic acid obtained has the highest affi nity to the target molecule (Fig. 1) . SELEX method can be modifi ed in a variety of ways to increase the specifi city of aptamer and effi ciency of SELEX.
Counter-SELEX
The counter-SELEX method was introduced to increase the effi ciency of aptamer selection by traditional SELEX (Fig.  1) (Jenison et al., 1994) . Compared to traditional SELEX, counter-SELEX has a pre-clearing step using closely related structural analogs of the target to effectively discard non-spe- Fig. 1 . Overview of SELEX scheme. Aptamers can be obtained through an iterative selection process known as SELEX (systematic evolution of ligands by exponential enrichment) by using single-stranded DNA or RNA. An initial pool of 10 14 -10 15 random oligonucleotide (ONT) strands are subjected to binding with the target. Unbound ONTs are discarded and RT-PCR or PCR is performed to amplify the targetbound ONTs. This selection process is repeated 6-15 times using amplifi ed ONTs as a new pool. This way, aptamers having high specifi city and affi nity are screened. Diverse molecules can be the target of the SELEX, including metal ion, protein, organic compound and cell. Toggle-SELEX performs SELEX with two different target molecules to obtain bispecifi c aptamers.
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Cell-SELEX
The SELEX target is not limited to an individual molecule. The cell-SELEX strategy has been described that utilizes living cells as the SELEX target (Fig. 1) . Although traditional SELEX is typically carried out using purifi ed target molecules, whole live cells are also employed as selection targets. Not only normal/abnormal mammalian cells such as virus-infected and cancer cells but also live pathogenic organisms such as bacteria and viruses have been utilized as cell-SELEX targets (Tang et al., 2009; Hamula et al., 2011) . The aptamers generated are functional with an original conformation of the target molecule on live cells. Compared to aptamers selected using a purifi ed target, a cell-SELEX-derived aptamer has more possibility to be used directly for in vivo and clinical applications. A screened aptamer resulting from cell-SELEX using abnormal cells can be used to detect disease or cancer. Moreover, biomarkers can be used to identify the aptamer target for a specifi c abnormality (Blank et al., 2001) . Many strategies are available to select an anti-virus aptamer. First, SELEX can be performed using the virion directly (Wang et al., 2000) . Second, aptamers can be generated that specifi cally bind to virus-infected cells. Through virus infection, viral proteins exist on the host cell surface due to the viral gene or enveloped protein. SELEX provides screening of virus-specifi c aptamers that recognize virus infected cells. Furthermore, aptamers can be selected for host cell proteins if their expression levels are upregulated upon viral infection. Lastly, stable cell lines can be generated that express viral protein as a cell-SELEX target, and the aptamer obtained can be used to detect virus infected cells . Furthermore, novel biomarkers can be discovered using the cell-SELEX technique. Because the target molecules of the aptamers generated by cell-SELEX may be previously unrecognized as cell-specifi c surface molecules, they could be novel biomarkers. Thus, cell-SELEX can be applied for de novo discovery of novel biomarkers for a desired cell by identifying the aptamer binding partner. The cell-SELEX concept can be extended for in vivo selection, which was fi rst designed using a hepatic tumor xenograft mouse model (Mi et al., 2010) . Oligonucleotides were injected intravenously, liver tumors were harvested, and the injected RNA molecules were extracted and amplifi ed. A tissue-specifi c aptamer can be more easily screened through this in vivo selection process. So, a screened aptamer may be a useful target for a tissue of interest without non-specifi c biodistribution in the in vivo application.
Capillary Electrophoresis-SELEX
The SELEX process has disadvantages in that it is time consuming to repeat the rounds. Some molecular biological methods have been introduced to SELEX to overcome these disadvantages. Capillary electrophoresis-SELEX (CE-SELEX) was designed for selecting aptamers to reduce repeating rounds with low dissociation constants (Mosing et al., 2005) . In this method, the nucleic acids that bind the target migrate with different mobilities than those of unbound sequences, allowing them to be collected as separate fractions. Although traditional SELEX requires 6-12 rounds, CE-SELEX signifi cantly reduces the number of rounds and increases binding affi nity (Schneider et al., 1995) . CE-SELEX decreases the time, effort, and cost to screen a higher affi nity aptamer compared to those of traditional SELEX. Based on CE technology, a non-SELEX method that selects an aptamer without amplifi cation was demonstrated (Berezovski et al., 2006) . Non-equilibrium capillary electrophoresis of equilibrium mixtures (NECEEM), a highly effi cient affi nity method, has been used to partition the DNA-target complex from the free DNA. An aptamer with nanomolar affi nity for the protein farnesyltransferase was selected in a single round of partitioning using NECEEM (Berezovski et al., 2005) . The advantage of non-SELEX is its speed and simplicity. NECEEM-based non-SELEX selection took only 1 h in contrast to several days or several weeks required for a traditional SELEX procedure by conventional partitioning methods. This procedure can be automated using a single commercially available capillary electrophoresis instrument.
One step MonoLEX
The MonoLEX approach combines a single affi nity chromatography step with subsequent physical segmentation of the affi nity resin and one single fi nal exponential amplifi cation step of the bound aptamers (Nitsche et al., 2007) . Using the Biomek 2000, an automatic SELEX device (Cox et al., 1998) , Cox et al. demonstrated that 10 rounds of selection against eight targets in parallel can be performed in 4-5 days.
Microfl uidic SELEX
Microfl uidic SELEX (mSELEX) was designed that combines traditional SELEX with a microfl uidic system. Protein immobilization is the most important aspect of mSELEX. A mSELEX prototype device was developed and biotinylated lysozymes were immobilized to silica microline previously coated with streptavidin (Hybarger et al., 2006) . In another study, a magnetic bead-based SELEX process with microfl uidics technology and a continuous-fl ow magnetic activated chipbased separation device was developed (Lou et al., 2009) . Using this mSELEX method, an enriched aptamer pool was obtained that tightly bound to the light chain of recombinant Botulinum neurotoxin type A after a single round of selection Kasahara and Kuwahara, 2012) . The simplest ribose 2' modifi cation is widely used to increase aptamer stability in vivo. Phosphate and base modifi cation are also used for this purpose. Substitution of F, OCH 3 , SH or CH 2 OH for 2'-OH (H) is widely used. BNA/LNA was designed to structurally protect 2' site. In addition, thiol (S) or borane (BH 3 ) group is introduced to α phosphate to strengthen oligonucleotide backbone. Functional groups can also be introduced into the base.
www.biomolther.org with a 33 nM Kd value. Recently, a novel formulation of solgel protein microarray material was developed, which elicited physical properties suitable for protein immobilization, proteinprotein interactions, and immunoassays (Kim et al., 2006) . Based on sol-gel, the authors developed a microfl uidic device and method for binding nucleic acids to immobilized proteins and effi ciently eluting and recovering the intact nucleic acids (Park et al., 2009) . The mSELEX system enhanced selection effi ciency and reduced time and effort compared to those of traditional SELEX.
Toggle-SELEX
Furthermore, toggle-SELEX has been established for in vitro animal model assays using a single aptamer (Fig. 1) . The "toggle" selection process was repeated during SELEX rounds using a target applied to human thrombin for even rounds and porcine thrombin for odd rounds to select a species cross-reactive aptamer (White et al., 2001) . A species cross-reactive aptamer from the toggle-SELEX strategy may contribute directly to animal models and clinical applications. Thus, toggle-SELEX makes the aptamer technique closer to a "bench-to-clinic" concept.
Based on these novel methods, high-throughput screening of aptamers and improved effi ciency of the SELEX process is possible. Moreover, consilience technology such as microfl uidic technology and engineering could reduce effort, time, and cost of aptamer selection and analysis, while increasing its effi cacy. Taken together, aptamers may play a key role in future theragnosis because of higher binding affi nity, lower cost, and ease of synthesis compared to antibodies.
STABILIZATION OF THE OLIGONUCLEOTIDE APTAMER
One of the ultimate goals during aptamer selection is a clinical application or an escort molecule. However, unmodifi ed nucleic acids per se are unstable in biological fl uids due to enzymatic degradation or a short half-life. Various strategies have been established to increase serum stability and overcome the degradation of oligonucleotides by nuclease (Fig. 2, 3) .
For example, the fi rst FDA-approved aptamer drug Macugen, which specifi cally binds to VEGF 165 , is a modifi ed oligonucleotide prepared by SELEX processes (Ruckman et al., 1998) . The RNA aptamer was screened from a library of modifi ed RNAs involving 2'-fl uoropyrimidine nucleotides (U, C) and natural purine nucleotides (A, G) in which the 2′-posi- Fig. 4 . Applications of aptamer. Aptamer can be used as therapeutics, targeted drug delivery system (DDS) and imaging. These three parts can be put together using aptamer and conjugation in multifunctional probe. tion of ribose is a nuclease attack site. Then, the natural A and G are properly replaced with 2'-methoxy nucleotides to enhance nuclease resistance and avoid a decrease in affi nity. Like Macugen, 2'-fl uor or methoxy or amine substituted nucleotides was widely used to protect from nuclease (Zhou et al., 2008 (Zhou et al., , 2011a (Zhou et al., , 2011b (Fig. 3) . Additionally, 2'-thio (-SH), 2'-azido (-N 3 ), 2'-hydroxymethyl (-CH 2 OH) modifi ed nucleotides was developed for protection of oligonucleotide. Moreover, bridged/locked, S-glycerol, cyclohexenyl, and threose nucleic acid (BNA/LNA, S-GNA, CeNA, and TNA, respectively) were applied to aptamer building block Ichida et al., 2005; Kempeneers et al., 2005; Tsai et al., 2007; Kuwahara et al., 2008; Barciszewski et al., 2009; Kasahara et al., 2013) (Fig. 3) . For example, Schmidt group reported that LNA modifi cation increased plasma stability more than 2'-OMe modifi cation using TTA1 aptamer which bind to Tenascin-C (Schmidt et al., 2004) . Furthermore, for the substitute phosphodiester bond in backbone, 5'-(α-thio)triphosphates and 5'-(α-borano) triphosphates were developed (Andreola et al., 2000; Lato et al., 2002) , with increased stability in the biological milieu (Yang et al., 1999) . Moreover, peptide nucleic acid (PNA) whose sugar-phosphate backbone is changed to repeating N-(2-aminoethyl)-glycine units linked by peptide bonds, increases biostability (Wittung et al., 1994) . In other aspect, base modifi cation could increase aptamer stability in novel thrombin aptamer containing 5-(1-pentynyl)-2'-deoxyuridine (Latham et al., 1994) . In the thalidomide aptamer, a modifi ed deoxyuridine bearing a cationic functional group via a hydrophobic methylene linker at the C5 position (Shoji et al., 2007) could improve stability against nucleases and the binding affi nity to target. Fibrinogen aptamer using boronic acidmodifi ed thymidine-5'-triphosphate , TNFRSF9 aptamer using 5-tryptaminocarbonyl-dU (Vaught et al., 2010) were also reported (Fig. 3) . Certain thermophilic and mutant polymerases such as Pwo, Vent (exo-), Deep Vent (exo-), and KOD Dash have been actively developed for incorporation of modifi ed nucleotides during polymerization (Gudima et al., 1998; Kuwahara et al., 2003; Leal et al., 2006; Kuwahara et al., 2009; Veedu et al., 2009; Kuwahara et al., 2010) .
A chiral form of an aptamer is an alternative strategy to prevent enzymatic degradation in biological fl uids by altering nuclease recognition. NOXXON Pharma established Spiegelmer (from German Spiegel "mirror", Fig. 2 ) to screen nucleaseresistant aptamers, which are RNA-like molecules built from L-ribose units. This Spiegelmer technology circumvents nuclease activity in biological fl uids. In short, a chiral form of the target molecule and D-form oligonucleotides are used during the SELEX process. Subsequently, an L-form of the aptamer is synthesized that has the same sequence as the selected Dform aptamer. Thus, an enzymatic degradation-insensitive aptamer, which also binds to the original target molecule, can be obtained (Fig. 2) Nolte et al., 1996; Williams et al., 1997; Leva et al., 2002) .
Several authors have inhibited in vivo clearance to increase half-life of aptamers. An anti-platelet derived growth factor aptamer was conjugated with 40 kDa polyethylene glycol (PEG) to slow down renal clearance (Floege et al., 1999) . In another study, Healy et al. reported an aptamer conjugated with 20 and 40 kDa PEG to prolong aptamer half-life in circulation (Healy et al., 2004) . Furthermore, the DNA aptamer ARCC1779, which binds to the A1 domain of the von Willebrand factor, was also 5′-conjugated with a 20 kDa PEG to reduce renal fi ltration (Diener et al., 2009) . Many studies are underway to increase the biostability and half-life of aptamers in different settings. However, post-SELEX modifi cation can infl uence target binding affi nity or secondary and tertiary structure formation, which, in turn, can alter aptamer function.
APTAMERS AS AGONISTS/ANTAGONISTS
Individual aptamers can be equipped in a modular manner with additional functions and can be specifi cally tailored for many potential applications in biotechnology and molecular medicine (Fig. 4) . In most cases, aptamers not only bind their cognate protein but also effi ciently inhibit the function of target as an antagonist. Many aptamer therapeutic studies have been conducted to treat certain diseases by inhibiting therapeutic target activity and decreasing the partner binding property (Holahan et al., 2011; Gissel et al., 2012; Siller-Matula et al., 2012; Vater et al., 2013) . Macugen, the fi rst FDAapproved aptamer drug for age-related macular degeneration, is a typical antagonistic aptamer (Zhou and Wang, 2006) . Macugen (pegaptanib) is a 28-base RNA oligonucleotide with two branched 20 kDa PEG moieties (Ruckman et al., 1998) . It selectively binds to the vascular endothelial growth factor (VEGF) 165 isoform when introduced intravitreally. Thus, the intracellular signal cascade is inhibited by the pegaptanib-VEGF 165 complex, which cannot bind to the VEGF receptor. Thus, pegaptanib has the potential to inhibit growth of blood vessels and vascular leakage by inhibiting the intracellular signal cascade induced by the pegaptanib-VEGF 165 complex. Diverse therapeutics based on antagonistic functions of aptamers are undergoing clinical trials (Table 1) . They inhibit the signaling cascade by decreasing activity of the target protein or altering binding with the physiological binding partner.
The fi rst report about aptamers as agonists came from the study that reported agonistic use of an aptamer with 4-1BB, which is a major costimulatory receptor (McNamara et al., 2008) . 4-1BB increased expansion and survival of activated T cells. Dimerization of the anti-4-1BB aptamer treated with the CD3 antibody not only increased T-cell activation and interferon-γ in vitro but also tumor regression in vivo. Moreover, Dollins et al. designed an aptamer-based agonist by dimerizing the OX4 RNA aptamer, which targets one of the tumor necrosis factor receptor families (Dollins et al., 2008) . Two 2′-fl uoropyrimidine-modifi ed RNA aptamers were selected that bind to CD28 (CD28Apt2 and CD28Apt7) . That study suggested that an agonistic dimerized anti-CD28 aptamer increases costimulatory effi cacy and reduces therapeutic dose and toxicity compared to conventional agonistic anti-CD28 antibodies. Similar research on aptamers for use as costimulatory agonistic molecules is being conducted (Suntharalingam et al., 2006; Römer et al., 2011) . Moreover, not only homodimerization of an aptamer for agonistic use but also heterodimerization of two individual aptamers that recognize different targets for dual purposes, specifi c targeting and stimulating, have been reported . Two individual aptamers were heterodimerized including a 4-1BB binding aptamer to stimulate the immune response and a prostate-specifi c membrane antigen (PSMA) binding aptamer for prostate cancer targeting. This bispecifi c aptamer was developed to regress prostate tumors through the host immune response. A bispecifi c aptamer is more effective than and synergizes with vaccination and exhibits a superior therapeutic index compared with nontargeted costimulation with 4-1BB antibodies or 4-1BB aptamers. Agonistic/antagonistic aptamers offer signifi cant advantages over antibodies in terms of synthesis, cost, and immunogenicity as well as conjugation chemistry.
TARGETED DRUG DELIVERY
Targeted drug delivery is one of the most important areas in therapeutic research. Aptamers exhibit many desirable properties for targeted drug delivery such as ease of selection and synthesis, high binding affi nity and specifi city, low immunogenicity, and versatile synthetic accessibility. The therapeutic agents that have been delivered using aptamers as the targeting ligands can be categorized into three major classes of drugs, toxins, and small interfering RNAs (siRNAs) (Fig. 4 ) . Doxorubicin (Dox) used in chemotherapy for hematological malignancies, carcinomas, and soft tissue sarcomas can intercalate within the double-stranded CG sequences of DNA and RNA. Based on the intercalation property of Dox to the aptamer, targeted Dox delivery for targeting cancer and Doxmediated cancer therapy has been actively studied Meng et al., 2012; Subramanian et al., 2012) . A Dox intercalated aptamer that binds to PSMA, which is abundantly expressed on the cell surface of a human prostatic adenocarcinoma (LNCaP) metastatic lesion has been studied. PSMA expressing LNCaP-specifi c cell death was observed by treatment of Dox-intercalated PSMA-specifi c 2′-fl uoropyrimidine aptamer, but not in PSMA-negative PC3 cells (Bagalkot et al., 2006) . Covalent conjugation of aptamer harboring the drug is relatively stable such that drug release during transport is prevented before the drug localizes at its cellular target. Drugs can be chemically modifi ed to form stable ester, amide, and disulfi de bonds that serve to conjugate the drug to the aptamer. The sgc8c DNA aptamer which specifi cally binds to protein tyrosine kinase 7 (PTK7) was covalently conjugated with Dox using hydrazone (Huang et al., 2009) . As a result, PTK7 expressing CCRF-CEM cell-specifi c Dox delivery and cell death were observed. Other chemotherapy drugs such as daunorubicin, thalidomide, and dactinoimycin can also intercalate to double-stranded oligonucleotides. They are expected to show a good therapeutic effect in specifi c cancers, and their application in various aptamers is actively sought.
The small size and lipid bilayer structure of liposomes make them an excellent drug delivery carrier. Aptamer-tagged liposomes were established that contained the anticancer drug paclitaxel and a fl uorescent dye (Nile Red) for tumor-specifi c drug delivery and imaging (Aravind et al., 2012) . In another study, Cy3-labeled, carboxylated, thiolated oligonucleotide aptamer (thioaptamer) against E-selectin (ESTA, E-Selectin ThioAptamer) was designed. This modifi ed ESTA was coupled to an amino PEGylated stealth liposome to make the vasculature targeting ESTA-conjugated liposome (Mann et al., 2011) , which achieved tumor vasculature-specifi c drug delivery. Similarly, this aptamer can be covalently coupled via NHS chemistry to toxic proteins. The targeting properties of the anti-PSMA aptamer can also be combined with the toxic characteristics http://dx.doi.org/10.4062/biomolther.2013.085 of gelonin, a ribosomal toxin (Chu et al., 2006a) . Moreover, a photosensitizer-aptamer conjugate was developed for cancerspecifi c delivery to be used in photodynamic cancer therapy (Yang et al., 2011; Han et al., 2013) .
siRNA delivery to specifi c cells using an aptamer has been actively investigated. In these studies, receptor-mediated endocytosis of the aptamer is necessary. In general, non-covalent conjugation through a connector and covalent linkage through formation of an aptamer-siRNA chimera are two major strategies for aptamer and siRNA conjugation. In 2006, two biotinylated anti-PSMA aptamers were linked to two biotinylated anti-lamin A/C siRNAs using streptavidin as the connector (Chu et al., 2006b) . As a result, PSMA-positive prostate cancer cell-specifi c siRNA was internalized and siRNA-specifi c gene expression was inhibited in vitro. However, the siRNA release mechanism and an in vivo experiment have not been demonstrated. The "sticky bridge" concept was used to noncovalently conjugate the anti-gp120 aptamer with siRNAs to suppress HIV replication in vitro ). An aptamer-siRNA chimera was developed using an aptamer consisting of single-stranded oligonucleotides. An aptamer was covalently linked to the passenger strands of siRNAs followed by annealing of the siRNA guide strands to the passenger strands to create a functional siRNA duplex (McNamara et al., 2006) . That study found that aptamer-siRNA chimera-mediated gene silencing was dependent on Dicer and occurred via the RNAi pathway. Moreover, anti-PSMA aptamer-Plk1 did not trigger interferon responses in vitro, and promoted tumor regression in a xenograft model of prostate cancer. Structural modifi cations were introduced that increased the valency of the chimera aptamer to enhance therapeutic effi cacy of the aptamer-siRNA targeting PSMA-expressing system (Wullner et al., 2008) . In their design, the siRNA sequence served as a linker to join the two aptamers, or to join the 3′ end of one of the aptamer dimers as a shRNA. Such modifi cations did not affect the critical sequence of the targeting regions and facilitated formation of the active conformation. Targeted siRNA delivery using an aptamer-siRNA chimera is being actively studied (Neff et al., 2011; Zhu et al., 2012b; Hussain et al., 2013) .
APTAMER-BASED IMAGING
Another application of aptamers is diagnosis via in vivo and in vitro imaging, using an aptamer that is conjugated to a fl uorophore, quantum dots, or other material such as gadolinium, which is useful for magnetic resonance imaging (MRI) (Fig. 4) . Optical imaging is a cost-effective imaging method that typically uses fl uorescent or bioluminescent molecules. Aptamerbased optical imaging can be divided into direct targeting and activatable probes . Direct conjugation with an aptamer and a fl uorescent molecule is widely studied (Shi et al., 2010; Cui et al., 2011; Talbot et al., 2011; Zhang et al., 2012; Song et al., 2013; Zhang et al., 2013) . It is the simplest way to image via a visualized aptamer by fl uorescence. Activatable probes are based on conformational changes in aptamer. It is designed such that fl uorescence will "turn-on" when the aptamer binds to its target. Typically, a fl uorescently labeled substrate is designed to be maximally quenched by a quencher in close proximity because of FRET (McIntyre and Matrisian et al., 2003; Tsien, 2005) . For example, Zhang et al., designed a bifunctional fl uorescent oligonucleotide probe for the detection of adenosine triphosphate (ATP) and thrombin (Tmb). The molecular beacon contains two hairpin loops that serve as the sensing elements, and a fl uorophore at one end and a quencher at the opposite end, as the reporter . "Turn-on" of fl uorescence mechanism by quenching is widely used in aptamer-based biosensor. Comparing to a conventional "always-on" probe, the activatable probe could substantially minimize the background signal originating from non-target tissues, thereby giving signifi cantly enhanced image contrast . Not only optical imaging, but superparamagnetic iron oxide nanoparticle-aptamer conjugate was used to MR imaging (Yigit et al., 2007) . T1-weighted MR imaging was designed that uses aptamer-gadolinium-tetraazacyclododecanetetraacetic acid (DOTA-Gd) (Xu and Lu, 2011) . It consists of anti-adenosine aptamer and its complementary sequence which conjugated with DOTA-Gd. Formation of adenosine-aptamer complex leads to release of DOTAGd-complementary sequence, which allows MR imaging.
Aptamer can also be applied for targeted ultrasound imaging using covalent conjugation of nanobubbles . These aptamer-conjugated nanobubbles can be harnessed to release certain amount of drugs upon targeted ultrasound-trigger (Maul et al., 2010) . Another application of aptamer is radioisotope labeling and its use in SPECT and PET. The TTA1 aptamer that can bind to tenascin-C, which is overexpressed in many solid tumors, was labeled with 99m Tc for SPECT imaging (Hicke et al., 2006) . 99m Tc-labeled TTA1 aptamer exhibited rapid blood clearance with a circulation half-life of <2 min but tumor penetration in several xenograft models. The durable tumor retention in combination with fast blood clearance yielded an excellent tumor-to-blood ratio, and various tumors were clearly visualized by planar scintigraphy. Furthermore, PET imaging application was studied using 64 Cu-labeled RNA aptamer (Rockey et al., 2011) . In this study, the choice of chelators and radiolabeling parameters such as pH and temperature were investigated for the development of 64 Cu-labeled RNA aptamers for potential PET imaging. In other aspect, aptamer can be coupled to iodinated nanoparticles (NPs) or polymer-coated Bi 2 S 3 NPs which can be used as computed tomography (CT) contrast agents (Cai and Chen, 2007) . Because each imaging method has its own advantages and disadvantages, a multimodality imaging probe based on AS1411 aptamer was evaluated (Hwang et al., 2010) . For this purpose, a cobalt-ferrite NP coated with rhodamine was modifi ed with the AS1411 aptamer, which was then conjugated to a chelating agent and further labeled with 67 Ga. This multimodal imaging probe could be simultaneously used for fl uorescence, gamma camera and MR imaging in vivo.
There are also attempts to not only image but simultaneously treat the disease. Diagnosis and therapy or theragnosis can be much simpler and easier when the disadvantages of each part are complemented through conjugation with aptamers. Recently, drug-loaded aptamer-gold nanoparticle (GNP) conjugate was designed for combined CT imaging and chemotherapy . The PSMA aptamer was conjugated with GNP for CT imaging, and Dox was loaded as a chemotherapeutic drug for prostate cancer targeting. This conjugate has been successfully used for targeting, imaging, and therapy of PMSA-expressing prostate cancer cells. Similarly, anti-mucin1 aptamer-QD-Dox conjugate was designed for optical imaging and chemotherapy of ovarian cancer (Salva et al., 2011) . The key to effective and successful imaging www.biomolther.org would be the development of delivery platforms having high effi ciency and ultrasensitive molecular probes for specifi c targets of interest.
SUMMARY AND CONCLUSIONS
Aptamers have many advantages compared to traditional targeting molecules and antibodies including high affi nity, low cost and immunogenicity, thermal stability, ease of production and high reproducibility. Diverse molecules such as chemotherapy drugs, toxins, siRNAs, imaging probes, and nanomaterials can be conjugated to aptamers, which serves to meet the increasing demand for versatile applications. Many new SELEX methods have been developed to easily and rapidly select for an aptamer. Compared to the traditional SELEX method, microfl uidic, CE-SELEX saves time and effort in addition to providing better affi nity and selectivity. In the near future, high-throughput selection of aptamers will allow various rapid aptamer selections and this will help to replace the role of antibodies in many applications from research to the clinic. Aptamers help to overcome the problem of immunogenicity when using antibodies in clinical applications and have provided a safe therapy and/or diagnosis without an immune response. Furthermore, aptamers are easily obtained by an in vitro chemical reaction and can overcome ethical issues of antibodies obtained from animals at a high cost. Natural oligonucleotides are unstable in biological fl uids because of endogenous nuclease. This problem can be addressed by using modifi ed oligonucleotides during SELEX or by a post-SELEX modifi cation. Although a modifi ed aptamer is obtained, careful consideration will be needed for post-SELEX modifications because the modifi cation can affect properties of the aptamer such as binding affi nity and/or function. Aptamers can be easily conjugated with other molecules in a chemical reaction. Aptamer-imaging probe conjugates can be used in various imaging modalities including optical imaging, MRI, PET, SPECT, CT, and ultrasound. Moreover, aptamers can also be conjugated with anti-cancer drugs. An aptamer-based multimodal imaging probe loaded with drug(s) will allow more precise real-time monitoring and therapy. The theragnostic potential of aptamer is gaining new momentum and will see a most auspicious development.
